Horizon Pharma Inc (HZNP) 38.41 $HZNP Stocks Struggle In

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Horizon Pharma Inc (HZNP) 38.41 $HZNP

Stocks Struggle In Mixed Terrain; Cummins, UPS, Horizon Rising
at Investor's Business Daily - Tue Jul 28, 9:50AM CDT
Stocks were tightly mixed at Tuesday's open, with earnings reports driving much of the early action. The Nasdaq, hamstrung by Baidu's (BIDU) 14% decline, fought with a fractional loss. The Dow Jones industrial average and the S&P 500 each added 0.2%....
F: 14.88 (+0.33), PCAR: 64.33 (-0.32), GRUB: 32.20 (+1.19), UTHR: 168.19 (+2.41), JBLU: 22.83 (+0.48), UPS: 100.43 (+5.31), BIDU: 164.64 (-33.04), CMI: 128.33 (+4.55), HZNP: 38.41 (+2.28), HAWK: 44.20 (+0.65), STO: 16.47 (+0.63)

Horizon Pharma plc Announces Collaboration With Fox Chase Cancer Center to Study ACTIMMUNE(R) (interferon gamma-1b) in Combination With PD-1/PD-L1 Inhibitors in Various Forms of Cancer
Marketwired - Mon Jul 27, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma (bladder cancer) and renal cell carcinoma.
HZNP: 38.41 (+2.28)

Horizon Pharma
at Investor's Business Daily - Tue Jul 21, 5:45PM CDT
Horizon Pharma (HZNP) increased its unsolicited bid for Depomed (DEPO), offering a deal worth $33 a share in Horizon stock. It had previously bid $29.25 a share. Horizon shares rose 0.4% to 38.45. Depomed rose 1.7% to 33.28.
HZNP: 38.41 (+2.28), DEPO: 32.60 (+0.31)

Horizon Pharma Up on Expected Q2 Sales, 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 5:35PM CDT
Horizon Pharma (HZNP) was up 3.3% after the company announced encouraging expected net sales for the second quarter of 2015 and upped its 2015 guidance.
HZNP: 38.41 (+2.28), LGND: 106.60 (+4.05), ANAC: 152.66 (+8.36), AMAG: 66.55 (+1.48)

Horizon Raises Bid for Specialty Pharma Company Depomed
at The Street - Tue Jul 21, 5:32PM CDT
The offer comes just three months after Depomed purchases the diabetes-related pain drug Nucynta from a subsidiary of Johnson & Johnson.
JNJ: 98.98 (+0.70), HZNP: 38.41 (+2.28), DEPO: 32.60 (+0.31)

Horizon Pharma raises bid for Depomed to $33 per share
AP - Tue Jul 21, 11:33AM CDT
NEW YORK (AP) — Drugmaker Horizon Pharma PLC is boosting its offer for fellow drugmaker Depomed to $33 per share.
HZNP: 38.41 (+2.28), DEPO: 32.60 (+0.31)

Depomed Confirms Receipt of Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc
PR Newswire - Tue Jul 21, 10:23AM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company" today confirmed that it has received a purported revised, highly conditional, unsolicited; and non-binding proposal from Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" to acquire all of the outstanding shares of Depomed in an all-stock transaction currently valued at $33.00 per share (the "Revised Proposal".
HZNP: 38.41 (+2.28), DEPO: 32.60 (+0.31)

Horizon Pharma Raises Bid For Depomed; Both Stocks Up
at Investor's Business Daily - Tue Jul 21, 9:50AM CDT
Specialty drugmaker Horizon Pharma (HZNP) raised its unsolicited offer for Depomed (DEPO) Wednesday, sending both stocks up. Horizon proposed a deal worth $33 a share, all in Horizon stock, up from its earlier bid of $29.25, which Depomed rejected....
HZNP: 38.41 (+2.28), DEPO: 32.60 (+0.31)

Horizon Pharma plc Increases Offer for Depomed, Inc. to $33.00 per Share
Marketwired - Tue Jul 21, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that it has increased the value of its all-stock acquisition proposal to $33.00 per share from $29.25 per share, contingent on Depomed entering into good faith discussions regarding a transaction. The increased offer represents a 60 percent premium to the closing price of Depomed on July 6, 2015, the day prior to when Horizon's initial proposal was made public.
HZNP: 38.41 (+2.28)

'Mad Money' Lightning Round: You Want Yahoo!
at The Street - Tue Jul 21, 5:00AM CDT
Cramer says to stay away from Alibaba but go for Yahoo!
YHOO: 37.79 (-0.04), UA: 97.47 (+1.04), NLY: 9.81 (+0.18), WWE: 16.50 (+0.49), HZNP: 38.41 (+2.28), CSCO: 28.17 (-0.04), VGR: 24.45 (+0.28), BABA: 80.27 (-1.13)

Jim Cramer's 'Mad Money' Recap: Earnings Tsunami Heads Our Way
at The Street - Mon Jul 20, 7:31PM CDT
Cramer says you've got to listen to the commentary on earnings from Apple tomorrow, not to mention what's up with Microsoft and falling PC sales.
WWE: 16.50 (+0.49), DAL: 44.82 (+0.89), PYPL: 37.51 (+1.12), SBUX: 57.10 (+0.12), YHOO: 37.79 (-0.04), JNJ: 98.98 (+0.70), QCOM: 63.36 (+1.38), CMG: 729.02 (-2.42), HZNP: 38.41 (+2.28), RCPT: 227.80 (+0.71), AAL: 41.29 (+1.15), ABBV: 70.92 (+1.58), GOOGL: 658.92 (+0.65), CAT: 77.88 (+2.56), MSFT: 45.43 (+0.08), AAPL: 123.49 (+0.72), CSCO: 28.17 (-0.04), AMBA: 122.35 (+2.90), JOY: 26.09 (+0.26), KO: 40.48 (-0.06), AMZN: 524.80 (-6.61), ABT: 51.01 (+0.32), AXP: 75.31 (+0.39), FB: 95.10 (+0.93), LLY: 85.49 (+1.34), BA: 141.88 (+0.85), CELG: 135.92 (+3.36), NFLX: 107.70 (+1.27), UA: 97.47 (+1.04), NLY: 9.81 (+0.18), MCD: 97.21 (+1.17), VGR: 24.45 (+0.28), BABA: 80.27 (-1.13)

Stocks Turn Slightly Higher; Horizon Jumps On Outlook
at Investor's Business Daily - Mon Jul 20, 12:31PM CDT
Stocks turned small losses into modest gains Monday afternoon. Thanks to solar, online travel and software stocks, the Nasdaq led with a 0.3% gain. The Dow Jones industrial average and the S&P 500 rose 0.2% each. Earlier, the Nasdaq and the S&P 500...
FB: 95.10 (+0.93), MDSO: 54.03 (+1.20), HZNP: 38.41 (+2.28), HRTG: 24.54 (-0.23), TASR: 30.89 (+0.56)

Horizon Pharma Hits High As Q2 Sales Beat Street
at Investor's Business Daily - Mon Jul 20, 10:57AM CDT
Specialty drugmaker Horizon Pharma (HZNP) jumped to a new high in early trading Monday after it issued strong preliminary Q2 sales and raised its full-year guidance. Horizon said sales in the quarter were about $170 million to $172 million, roughly a...
HZNP: 38.41 (+2.28), DEPO: 32.60 (+0.31)

Horizon Pharma (HZNP) Stock Gains on Strong Guidance
at The Street - Mon Jul 20, 9:46AM CDT
Horizon Pharma (HZNP) shares are rising after the company provided upside second quarter and full year revenue guidance.
HZNP: 38.41 (+2.28)

Horizon Pharma plc Expects Record Net Sales Results for Second Quarter 2015 and Raises Full-Year 2015 Net Sales and Adjusted EBITDA Guidance
Marketwired - Mon Jul 20, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced expected record net sales results for the second quarter ended June 30, 2015.
HZNP: 38.41 (+2.28)

Critical Alerts For Chesapeake Energy, Starbucks, Horizon Pharma, Halozyme Therapeutics and Citigroup Released By InvestorsObserver
PR Newswire - Fri Jul 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CHK, SBUX, HZNP, HALO and C.
SBUX: 57.11 (+0.13), HALO: 24.02 (+1.22), CHK: 8.95 (+0.58), C: 58.31 (+0.35), HZNP: 38.41 (+2.28)

Depomed
at Investor's Business Daily - Mon Jul 13, 5:54PM CDT
Depomed (DEPO) stated in a regulatory filing that it has adopted a "poison pill" plan following Horizon Pharma's (HZNP) $2.1 bil hostile takeover bid, which Depomed has rejected. Depomed shares rose 1.2% to 30.51. Horizon Pharma fell 2.7% to 34.97.
HZNP: 38.41 (+2.28), DEPO: 32.60 (+0.31)

Horizon Pharma plc Responds to Depomed's Adoption of a Poison Pill
Marketwired - Mon Jul 13, 11:50AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today responded to the announcement by Depomed, Inc. that it has implemented a poison pill (also known as a "shareholder rights plan" and amended and restated its bylaws in a shareholder unfriendly manner.
HZNP: 38.41 (+2.28)

Will Horizon Pharma (HZNP) Stock be Hurt by DepoMed's Poison Pill?
at The Street - Mon Jul 13, 9:35AM CDT
Horizon Pharma (HZNP) shares are showing volatility after the object of its takeover interest, DepoMed (DEPO), adopted a poison pill to dissuade any further unsolicited offers.
HZNP: 38.41 (+2.28)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 188

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 164

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 53

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 149

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

New York Court Upholds Healthcare Rights for Retirees

Updated Category News Views 94

New York Court of Appeals Decision on Retiree Healthcare Rights In a landmark ruling, the New York Court of Appeals determined that the city is required to cover the total cost of the health insurance plans chosen by its retirees. This decision represents a significant win for over 250,000 retired workers and their families seeking to maintain their healthcare benefits....

Continue Reading
Corning's Strategic Path Amid AI Trends and Market Challenges

Updated Category News Views 1824

Corning Incorporated (NYSE: GLW) hit a crossroads back in 2024 as it tried to balance rising AI trends with challenges lurking in traditional markets. Renowned for its expertise in materials science, particularly specialty glass and optical physics, Corning was looking to leverage these trends while facing stiff competition and economic uncertainties. Quarterly...

Continue Reading
Innovating the Future: The Inaugural Global Quantum Forum

Updated Category News Views 274

Inaugural Global Quantum Forum Set to Launch During TechChicago Week The upcoming Global Quantum Forum promises to be a landmark event for the quantum industry, coinciding with the much-anticipated TechChicago Week. This two-day conference is positioned to take place in an exciting environment where innovation meets collaboration. With over 70 distinguished speakers,...

Continue Reading
Oil Prices React to US Supply and Rising Geopolitical Risks

Updated Category News Views 83

Oil Market Overview: Supply Dynamics and Geopolitical Tensions As oil prices faced a dip recently, analysts found that U.S. supply levels play a significant role in shaping market trends. The weekly report reflecting increased U.S. crude and gasoline stocks was a key factor influencing the downturn. Insights on Current Oil Price Performance Brent crude futures for January...

Continue Reading
Senator McConnell's Recent Stock Purchase Insights and Implications

Updated Category News Views 160

Insights into Senator McConnell's Stock Purchase Recently, it has come to public attention that Senator A. Mitchell McConnell, Jr. has made a notable financial move by purchasing stock in Wells Fargo (NYSE: WFC). This purchase, reported to be valued between $1,001 and $15,000, is part of a pattern of trading activity that might have implications for investors and stock...

Continue Reading